Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
Globe Newswire•01/10/2026•09:01 ET
0
Key Highlights
- ➤CMS application submitted for permanent product-specific J-code for LYTENAVA (OTLK)
- ➤U.S. commercial launch remains on track before year-end 2026
- ➤Permanent J-code could streamline billing and support practice adoption
- ➤CMS submission does not guarantee J-code assignment or reimbursement
Expert Statements
Bob Jahr, Chief Executive Officer of Outlook Therapeutics
“This submission represents a critical step toward securing a permanent, product-specific J-code for LYTENAVA and establishing a clear and consistent reimbursement pathway for U.S. retina practices.”
Bob Jahr, Chief Executive Officer of Outlook Therapeutics
“A permanent J-code would streamline billing, reduce administrative burden and support broader practice adoption and patient access.”
Bob Jahr, Chief Executive Officer of Outlook Therapeutics
“We remain focused on executing across market access, reimbursement, commercial readiness and supply ahead of our planned U.S. launch before the end of 2026.”
Application represents an important step in supporting reimbursement
Company remains on track for U.S. commercial launch of LYTENAVA before year-end 2026
Get started
Create a free account to read the full story.